PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-26.31%
R&D reduction while AVXL shows 96.36% growth. Joel Greenblatt would examine competitive risk.
-49.44%
G&A reduction while AVXL shows 58.14% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
3.87%
Other expenses change of 3.87% while AVXL maintains costs. Bruce Berkowitz would investigate efficiency.
-37.34%
Operating expenses reduction while AVXL shows 76.27% growth. Joel Greenblatt would examine advantage.
-37.34%
Total costs reduction while AVXL shows 76.27% growth. Joel Greenblatt would examine advantage.
-62.14%
Both companies reducing interest expense. Martin Whitman would check industry trends.
3.87%
D&A growth while AVXL reduces D&A. John Neff would investigate differences.
47.24%
EBITDA growth while AVXL declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
37.34%
Operating income growth while AVXL declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
1271.24%
Other expenses growth while AVXL reduces costs. John Neff would investigate differences.
47.13%
Pre-tax income growth while AVXL declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-62.14%
Tax expense reduction while AVXL shows 214.74% growth. Joel Greenblatt would examine advantage.
47.13%
Net income growth while AVXL declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
50.90%
EPS growth while AVXL declines. John Neff would investigate advantages.
52.86%
Diluted EPS growth while AVXL declines. John Neff would investigate advantages.
7.67%
Share count reduction exceeding 1.5x AVXL's 33.28%. David Dodd would verify capital allocation.
12.32%
Diluted share reduction exceeding 1.5x AVXL's 33.28%. David Dodd would verify capital allocation.